Aperio Appoints Cari Kniola Director of Corporate Strategy

DOORwaY-90 Study for SIR-Spheres® Therapy as 1st-line Treatment for Hepatocellular Carcinoma Enrolls First Patient

The study will assess the duration of response (DoR) and objective response rate (ORR) of SIR-Spheres. It is being led by co-principal investigators Cheenu Kappadath, PhD and Dr. Armeen Mahvash.

Global Surgical Lasers Market to Reach $10.1 Billion by 2027

1 Billion by 2027, growing at a CAGR of 9.7% over the analysis period 2020-2027. Solid-State Laser Systems, one of the segments analyzed in the report, is projected to record a 9.2% CAGR and reach US$3.9 Billion by the end of the analysis period.

Carestream Health Advances X-ray Image Quality with Smart Noise Cancellation

SNC has received FDA 510(k) Clearance and is available as an optional feature with Carestream’s ImageView Software powered by Eclipse—the intelligent image-processing engine behind the company’s innovative imaging software—on DRX-Evolution and DRX-Evolution Plus systems.

Today Aperio Clinical Outcomes announced the appointment of Cari Kniola who will serve as their Director of Corporate Strategy.

The company reports Kniola has over 20 years of clinical research experience in the medical device and pharma industries, ranging from a clinical research associate through project management of global studies at both sponsor companies and CROs. This experience is combined with an appreciation for Aperio’s culture and the need to preserve it as the company continues to grow and evolve. This strategic growth occurs as Aperio continues to match pace with a clinical research industry experiencing emerging technologies, novel treatments and an ever-changing regulatory landscape. Kniola will lead through oversight of proposal and marketing strategy, strategic business development and service partnerships.

Says Faye Woolf, Aperio’s Founder and CEO, “We want to make sure to continue to grow Aperio in a way that maximizes our potential while being true to who we are, all the while providing our services with the utmost quality and integrity. We are so fortunate to have Cari’s natural inclination towards strategy and creative solutions coupled with a vast background in the industry to ensure we maintain our core principles as Aperio makes its mark in the industry.”

“My entire career has been involved in clinical research, and I thrive on the creative process and seeing strategic visions come to fruition,” says Kniola. “I am excited to take both my ‘real world’ experience and my innate skills and use them together to help strategize the growth of Aperio. We have a team of people at Aperio who are passionate about what they do, with an amazing depth and breadth of experience in clinical development. With our high caliber teams, our culture of quality and transparency, and our ability to evolve as the industry evolves, the possibilities are limitless for Aperio’s continued growth as an agile and innovative CRO services provider.”



Subscribe to Medical Device News Magazine here.

Related Articles